Paper · 42226254
Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection.
Jiao G and 8 others. Mol Cancer, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection. Papers, record 42226254. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42226254
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Bispecific | Major topic |
| Neoplasms | Major topic |
| T-Lymphocytes | Major topic |
| Antineoplastic Agents, Immunological | Major topic |
| Humans | |
| Animals | |
| Tumor Microenvironment | |
| Immunotherapy |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 0065/2025/ITP1 | the Science and Technology Development Fund of Macau | PubMed | ||
| FDCT/0150/2025/AFJ | the Science and Technology Development Fund of Macau | PubMed | ||
| MYRG-GRG2024-00172-FHS | the University of Macau | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References238
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40,640,393 | A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. | Nat Med | 2025 | https://conductscience.org/library/papers/40640393 | PubMed |
| 2 | 33,255,436 | Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33255436 | PubMed |
| 3 | 39,041,287 | Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy. | MAbs | 2024 | https://conductscience.org/library/papers/39041287 | PubMed |
| 4 | 39,424,778 | PD-1 and LAG-3: synergistic fostering of T cell exhaustion. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39424778 | PubMed |
| 5 | 39,982,632 | A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs. | Invest New Drugs | 2025 | https://conductscience.org/library/papers/39982632 | PubMed |
| 6 | 37,355,214 | Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects. | Semin Cancer Biol | 2023 | https://conductscience.org/library/papers/37355214 | PubMed |
| 7 | 37,879,536 | A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. | J Thorac Oncol | 2024 | https://conductscience.org/library/papers/37879536 | PubMed |
| 8 | 40,243,372 | Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications. | Immun Inflamm Dis | 2025 | https://conductscience.org/library/papers/40243372 | PubMed |
| 9 | 41,613,111 | The role of immune checkpoint molecules in cancers. | Front Immunol | 2025 | https://conductscience.org/library/papers/41613111 | PubMed |
| 10 | 22,804,669 | Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. | Br J Haematol | 2012 | https://conductscience.org/library/papers/22804669 | PubMed |
1 to 10 of 238
See all 238 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TRBV20OR9-2 | 6,962 | PubTator's text mining | https://conductscience.org/library/genes/6962 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42226254
GET https://conductscience.org/api/papers/v1/42226254/references?page=2